Cost Effectiveness of Combination Therapy with Pioglitazone for Type 2 Diabetes Mellitus from a German Statutory Healthcare Perspective

This publication has 70 references indexed in Scilit:

• Applications of Economic Models in Healthcare
  PharmacoEconomics, 2002
• Pioglitazone
  Drugs, 2000
• UKPDS 28: A Randomized Trial of Efficacy of Early Addition of Metformin in Sulfonylurea-Treated Type 2 Diabetes
  Diabetes Care, 1998
• Evaluation of the Potential Clinical and Economic Effects of Bodyweight Stabilisation with Acarbose in Patients with Type 2 Diabetes Mellitus
  PharmacoEconomics, 1998
• Economic implications of the Total Ischaemic Burden Bisoprolol Study (TIBBS) follow-up
  Journal of Medical Economics, 1998
• Hypertriglyceridemia and elevated lipoprotein (a) are risk factors for major coronary events in middle-aged men
  The American Journal of Cardiology, 1996
• Therapeutic Comparison of Metformin and Sulfonylurea, Alone and in Various Combinations: A double-blind controlled study
  Diabetes Care, 1994
• Probability of stroke: a risk profile from the Framingham Study.
  Stroke, 1991
• Cardiovascular disease risk profiles
  American Heart Journal, 1991
• A new approach to causal inference in mortality studies with a sustained exposure period—application to control of the healthy worker survivor effect
  Mathematical Modelling, 1986